Compounders Research Compare

Dianthus Therapeutics, Inc.(DNTH)

Biotechnology · New York, NY

$84.42-3.62 (-4.11%)

Delayed quote: Oct 6, 2026, 10:45 AM EDT

About Dianthus Therapeutics, Inc.

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

New York, NY

92 employees

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Marino Garcia

View full financials

Earnings Yield: N/A

Basis: Unrounded diluted TTM EPS / FMP quote price × 100. Source: stored company filings and market data; unavailable inputs remain N/A.

The earnings yield is N/A as of 2026-10-06T14:46:27.661Z.

Stored calculation inputs

Calculation as of: 2026-10-06T14:46:27.661Z.

Quote observation: 2026-10-06T14:45:13.000Z. Amounts in USD. The price header may show a later quote.

Unrounded diluted TTM EPS · period ending 2026-06-30: -0.13
Quote price: 84.4194

FMP input reference: 6dae1ed753b385efcb651dd8f32a10b6f9886011747f410ddce9f57bee9a14c9

P/E Ratio|FCF Yield|Dividend Yield|All Metrics

DNTH Earnings Yield Metrics

EARNINGS YIELD

N/A

DNTH Competitors' Earnings Yield

Dianthus Therapeutics, Inc.

Current

Market Cap

$4.72B

Earnings Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

BillionToOne, Inc.

Market Cap

$4.71B

Earnings Yield

0.61%

TTM Avg

0.37%

3Y Avg

0.37%

5Y Avg

0.37%

LifeStance Health Group, Inc.

Market Cap

$4.65B

Earnings Yield

1.08%

TTM Avg

0.64%

3Y Avg

0.64%

5Y Avg

0.64%

Mirum Pharmaceuticals, Inc.

Market Cap

$4.81B

Earnings Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Definium Therapeutics, Inc.

Market Cap

$4.59B

Earnings Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Erasca, Inc.

Market Cap

$4.89B

Earnings Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Adaptive Biotechnologies Corporation

Market Cap

$4.43B

Earnings Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Scholar Rock Holding Corporation

Market Cap

$5.05B

Earnings Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Indivior Pharmaceuticals Inc

Market Cap

$4.38B

Earnings Yield

7.95%

TTM Avg

5.11%

3Y Avg

3.07%

5Y Avg

3.43%

Merit Medical Systems, Inc.

Market Cap

$5.07B

Earnings Yield

2.85%

TTM Avg

2.80%

3Y Avg

2.38%

5Y Avg

2.05%

NAME	MARKET CAP	EARNINGS YIELD	TTM	3Y	5Y
Dianthus Therapeutics, Inc. (DNTH)	$4.72B	N/A	N/A	N/A	N/A
BillionToOne, Inc. (BLLN)vs ›	$4.71B	0.61%	0.37%	0.37%	0.37%
LifeStance Health Group, Inc. (LFST)vs ›	$4.65B	1.08%	0.64%	0.64%	0.64%
Mirum Pharmaceuticals, Inc. (MIRM)vs ›	$4.81B	N/A	N/A	N/A	N/A
Definium Therapeutics, Inc. (DFTX)vs ›	$4.59B	N/A	N/A	N/A	N/A
Erasca, Inc. (ERAS)vs ›	$4.89B	N/A	N/A	N/A	N/A
Adaptive Biotechnologies Corporation (ADPT)vs ›	$4.43B	N/A	N/A	N/A	N/A
Scholar Rock Holding Corporation (SRRK)vs ›	$5.05B	N/A	N/A	N/A	N/A
Indivior Pharmaceuticals Inc (INDV)vs ›	$4.38B	7.95%	5.11%	3.07%	3.43%
Merit Medical Systems, Inc. (MMSI)vs ›	$5.07B	2.85%	2.80%	2.38%	2.05%

Earnings Yield vs P/E Ratio

Earnings Yield

N/A

EPS ÷ Price

P/E Ratio

N/A

Price ÷ EPS

Formula: Earnings Yield = (EPS / Price) × 100

Earnings Yield is simply the inverse of P/E. A P/E of 20 equals a 5% earnings yield.

How earnings yield is used:

It expresses earnings relative to share price as a percentage
It can be compared with FCF yield and dividend yield
It can be compared with bond yields because both are percentages
It is mathematically the inverse of the P/E ratio

Earnings Yield Formula & Definition

Earnings Yield = EPS (TTM) / Share Price

Earnings yield is the inverse of the PE ratio, expressing trailing earnings as a percentage of price. Higher is cheaper.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

P/E Ratio FCF Yield Dividend Yield All Metrics